» Articles » PMID: 24810336

MiR-199a-3p Displays Tumor Suppressor Functions in Papillary Thyroid Carcinoma

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 May 10
PMID 24810336
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer incidence is rapidly increasing. Papillary Thyroid Carcinoma (PTC), the most frequent hystotype, usually displays good prognosis, but no effective therapeutic options are available for the fraction of progressive PTC patients. BRAF and RET/PTC are the most frequent driving genetic lesions identified in PTC. We developed two complementary in vitro models based on RET/PTC1 oncogene, starting from the hypothesis that miRNAs modulated by a driving PTC-oncogene are likely to have a role in thyroid neoplastic processes. Through this strategy, we identified a panel of deregulated miRNAs. Among these we focused on miR-199a-3p and showed its under-expression in PTC specimens and cell lines. We demonstrated that miR-199a-3p restoration in PTC cells reduces MET and mTOR protein levels, impairs migration and proliferation and, more interesting, induces lethality through an unusual form of cell death similar to methuosis, caused by macropinocytosis dysregulation. Silencing MET or mTOR, both involved in survival pathways, does not recapitulate miR-199a-3p-induced cell lethality, thus suggesting that the cooperative regulation of multiple gene targets is necessary. Integrated analysis of miR-199a-3p targets unveils interesting networks including HGF and macropinocytosis pathways. Overall our results indicate miR-199a-3p as a tumor suppressor miRNA in PTC.

Citing Articles

Research on the expression of Mir-218-2 in the serum of patients with papillary thyroid cancer and its clinical significance.

He H, Hao D, Tian L, Zhu C, Guo L, Zhang K Eur J Transl Myol. 2024; 34(3).

PMID: 39221591 PMC: 11487670. DOI: 10.4081/ejtm.2024.12678.


Non-coding RNA-mediated epigenetic alterations in Grave's ophthalmopathy: A scoping systematic review.

Shahraki K, Pak V, Najafi A, Shahraki K, Boroumand P, Sheervalilou R Noncoding RNA Res. 2023; 8(3):426-450.

PMID: 37324526 PMC: 10265490. DOI: 10.1016/j.ncrna.2023.04.001.


Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression.

Dou X, Xia F, Li X Epigenetics. 2023; 18(1):2210339.

PMID: 37166441 PMC: 10177672. DOI: 10.1080/15592294.2023.2210339.


The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer.

Nachtigal M, Altman A, Arora R, Schweizer F, Arthur G Cancers (Basel). 2022; 14(14).

PMID: 35884379 PMC: 9322924. DOI: 10.3390/cancers14143318.


MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of .

Ho J, Chen J, Cheuk I, Siu M, Shin V, Kwong A Am J Transl Res. 2022; 14(3):2021-2036.

PMID: 35422914 PMC: 8991114.


References
1.
Sousa M, Latini F, Monteiro H, Cerutti J . Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. Free Radic Biol Med. 2010; 49(6):997-1007. DOI: 10.1016/j.freeradbiomed.2010.06.006. View

2.
Kitano M, Rahbari R, Patterson E, Xiong Y, Prasad N, Wang Y . Expression profiling of difficult-to-diagnose thyroid histologic subtypes shows distinct expression profiles and identify candidate diagnostic microRNAs. Ann Surg Oncol. 2011; 18(12):3443-52. PMC: 3474204. DOI: 10.1245/s10434-011-1766-4. View

3.
Borrello M, Alberti L, Fischer A, DeglInnocenti D, Ferrario C, Gariboldi M . Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A. 2005; 102(41):14825-30. PMC: 1253545. DOI: 10.1073/pnas.0503039102. View

4.
Shah D, Naciri M, Clee P, Al-Rubeai M . NucleoCounter-An efficient technique for the determination of cell number and viability in animal cell culture processes. Cytotechnology. 2008; 51(1):39-44. PMC: 3449478. DOI: 10.1007/s10616-006-9012-9. View

5.
Gu S, Chan W . Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Sci. 2012; 13(7):8449-8466. PMC: 3430244. DOI: 10.3390/ijms13078449. View